SOX plus sintilimab vs P-SOX vs SOX as neoadjuvant therapy in advanced gastric cancer: Efficacy and safety

Table 2 Side effects associated with three groups treatment, n (%)

Variables	Total (n = 299)	P-SOX (n = 118)	SOX (n = 100)	SOX + XDL (n = 81)	P value
Nausea and vomiting					0.786
0	63 (21.1)	24 (20.3)	20 (20)	19 (23.5)
1	171 (57.2)	65 (55.1)	62 (62)	44 (54.3)
2	58 (19.4)	27 (22.9)	16 (16)	15 (18.5)
3	7 (2.3)	2 (1.7)	2 (2)	3 (3.7)
Liver toxicity					0.912
0	254 (84.9)	100 (84.7)	83 (83)	71 (87.7)
1	39 (13)	15 (12.7)	15 (15)	9 (11.1)
2	6 (2)	3 (2.5)	2 (2)	1 (1.2)
Alopecia					0.009
0	178 (59.5)	64 (54.2)	53 (53)	61 (75.3)
1	107 (35.8)	46 (39)	42 (42)	19 (23.5)
2	14 (4.7)	8 (6.8)	5 (5)	1 (1.2)
Peripheral sensory neuropathy					0.426
0	143 (47.8)	51 (43.2)	54 (54)	38 (46.9)
1	124 (41.5)	50 (42.4)	40 (40)	34 (42)
2	27 (9)	15 (12.7)	5 (5)	7 (8.6)
3	5 (1.7)	2 (1.7)	1 (1)	2 (2.5)
Fewer neutrophils					0.231
0	218 (72.9)	88 (74.6)	70 (70)	60 (74.1)
1	52 (17.4)	23 (19.5)	17 (17)	12 (14.8)
2	18 (6)	3 (2.5)	7 (7)	8 (9.9)
3	10 (3.3)	3 (2.5)	6 (6)	1 (1.2)
4	1 (0.3)	1 (0.8)	0 (0)	0 (0)
Fewer white blood cells					0.838
0	196 (65.6)	80 (67.8)	65 (65)	51 (63)
1	66 (22.1)	23 (19.5)	21 (21)	22 (27.2)
2	26 (8.7)	9 (7.6)	10 (10)	7 (8.6)
3	7 (2.3)	3 (2.5)	3 (3)	1 (1.2)
4	4 (1.3)	3 (2.5)	1 (1)	0 (0)
Fewer platelets					0.457
0	215 (71.9)	87 (73.7)	72 (72)	56 (69.1)
1	54 (18.1)	19 (16.1)	20 (20)	15 (18.5)
2	25 (8.4)	10 (8.5)	5 (5)	10 (12.3)
3	5 (1.7)	2 (1.7)	3 (3)	0 (0)
Anemia					0.794
0	152 (50.8)	63 (53.4)	49 (49)	40 (49.4)
1	106 (35.5)	39 (33.1)	37 (37)	30 (37)
2	26 (8.7)	10 (8.5)	7 (7)	9 (11.1)
3	15 (5)	6 (5.1)	7 (7)	2 (2.5)

XDL: Sintilimab.